Drug Type Small molecule drug |
Synonyms Talnetant hydrochloride, Talnetant hydrochloride (USAN), SB 223242 + [5] |
Target |
Action antagonists |
Mechanism NK3 antagonists(Neurokinin 3 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H22N2O2 |
InChIKeyBIAVGWDGIJKWRM-FQEVSTJZSA-N |
CAS Registry174636-32-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Irritable Bowel Syndrome | Phase 2 | United States | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | Australia | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | Canada | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | France | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | Germany | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | Netherlands | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | South Africa | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | Spain | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | Sweden | 01 Oct 2004 | |
Irritable Bowel Syndrome | Phase 2 | United Kingdom | 01 Oct 2004 |